An evaluation of the societal costs and benefits of adjuvant trastuzumab in the treatment of early HER2neu-positive breast cancer in Singapore. Background: The era of cytostatic cancer agents requires ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback